• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

蛋白质组学在糖尿病及其并发症中的应用

陶颖君, 吴洁, 刘畅

陶颖君, 吴洁, 刘畅. 蛋白质组学在糖尿病及其并发症中的应用[J]. 中国药科大学学报, 2020, 51(3): 368-373. DOI: 10.11665/j.issn.1000-5048.20200315
引用本文: 陶颖君, 吴洁, 刘畅. 蛋白质组学在糖尿病及其并发症中的应用[J]. 中国药科大学学报, 2020, 51(3): 368-373. DOI: 10.11665/j.issn.1000-5048.20200315
TAO Yingjun, WU Jie, LIU Chang. Application of proteomics in diabetes and its complications[J]. Journal of China Pharmaceutical University, 2020, 51(3): 368-373. DOI: 10.11665/j.issn.1000-5048.20200315
Citation: TAO Yingjun, WU Jie, LIU Chang. Application of proteomics in diabetes and its complications[J]. Journal of China Pharmaceutical University, 2020, 51(3): 368-373. DOI: 10.11665/j.issn.1000-5048.20200315

蛋白质组学在糖尿病及其并发症中的应用

基金项目: 国家自然科学基金资助项目( No. 81673340)

Application of proteomics in diabetes and its complications

Funds: This study was supported by the National Natural Science Foundation of China ( No. 81673340)
  • 摘要: 蛋白质组学是近年来兴起的研究各种疾病的最前沿领域和热点之一,蛋白组学的发展为糖尿病早期诊断及治疗提供了新的研究方向并取得一定的研究成果,糖尿病早期诊断有助于控制患者的病情发展甚至免于手术治疗,对于改善患者预后具有重要意义。本文从蛋白质组学研究技术及其在糖尿病及并发症中应用的现状和前景进行了总结,就蛋白质组学的快速发展对糖尿病研究的影响以及在发现更多糖尿病生物标志物方面的积极作用进行了展望,未来的研究应更加注重发现生物标志物之间的相互联系,为糖尿病及其并发症的诊断与治疗提供新的思路。
    Abstract: Proteomics is one of the most advanced fields and hotspots in the research of various diseases in recent years. Its development has provided a new research direction for the early diagnosis and treatment of diabetes and has achieved some research results. Early diagnosis is helpful to control the progression of the disease or even avoid surgical treatment, which is of great significance for improving the prognosis of patients. This paper reviews the current status and prospects of proteomic technology and its applications in diabetes as well as its complications with a prospect of the impact of the rapid development of proteomics on diabetes and its positive role in discovering more diabetes biomarkers. In the future research, more attention should be paid to the interconnections between biomarkers.
  • [1] . Wiley Interdiscip Rev Syst Biol Med, 2019, 11(5): e1450.
    [2] Vaudel M, Barsnes H, R?der H, et al. Using proteomics bioinformatics tools and resources in proteogenomic studies[J]. Adv Exp Med Biol, 2016, 926: 65-75.
    [3] Joubert R, Strub JM, Zugmeyer S, et al. Identification by mass spectrometry of two-dimensional gel electrophoresis-separated proteins extracted from lager brewing yeast[J]. Electrophoresis, 2001, 22(14): 2969-2982.
    [4] Chen GD, Pramanik BN. Application of LC/MS to proteomics studies: current status and future prospects[J]. Drug Discov Today, 2009, 14(9/10): 465-471.
    [5] Cs?sz, Deák E, Kalló G, et al. Diabetic retinopathy: proteomic approaches to help the differential diagnosis and to understand the underlying molecular mechanisms[J]. J Proteomics, 2017, 150: 351-358.
    [6] Haythorne E, Rohm M, van de Bunt M, et al. Diabetes causes marked inhibition of mitochondrial metabolism in pancreatic β-cells[J]. Nat Commun, 2019, 10(1): 2474.
    [7] Mohan V, Radha V. Precision diabetes is slowly becoming a reality[J]. Med Princ Pract, 2019, 28(1): 1-9.
    [8] Wang Y, An HY, Liu T, et al. Metformin improves mitochondrial respiratory activity through activation of AMPK[J]. Cell Rep, 2019, 29(6): 1511-1523.e5.
    [9] Khan RMM, Chua ZJY, Tan JC, et al. From pre-diabetes to diabetes: diagnosis, treatments and translational research[J]. Medicina (Kaunas), 2019, 55(9): E546.
    [10] Metz TO, Qian WJ, Jacobs JM, et al. Application of proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody standardization program sample subset[J]. J Proteome Res, 2008, 7(2): 698-707.
    [11] Zhang QB, Fillmore TL, Schepmoes AA, et al. Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes[J]. J Exp Med, 2013, 210(1): 191-203.
    [12] Soggiu A, Piras C, Bonizzi L, et al. A discovery-phase urine proteomics investigation in type 1 diabetes[J]. Acta Diabetol, 2012, 49(6): 453-464.
    [13] Huth C, von Toerne C, Schederecker F, et al. Protein markers and risk of type 2 diabetes and prediabetes: a targeted proteomics approach in the Kora F4/FF4 study[J]. Eur J Epidemiol, 2019, 34(4): 409-422.
    [14] Lietzén N, Hirvonen K, Honkimaa A, et al. Coxsackievirus B persistence modifies the proteome and the secretome of pancreatic ductal cells[J]. iScience, 2019, 19: 340-357.
    [15] Lutty GA. Effects of diabetes on the eye[J]. Invest Ophthalmol Vis Sci, 2013, 54(14): ORSF81.
    [16] Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets[J]. Middle East Afr J Ophthalmol, 2012, 19(1): 52-59.
    [17] Whitehead M, Osborne A, Widdowson PS, et al. Angiopoietins in diabetic retinopathy: current understanding and therapeutic potential[J]. J Diabetes Res, 2019, 2019: 5140521.
    [18] Jin J, Min H, Kim SJ, et al. Development of diagnostic biomarkers for detecting diabetic retinopathy at early stages using quantitative proteomics[J]. J Diabetes Res, 2016, 2016: 6571976.
    [19] Torok Z, Peto T, Csosz E, et al. Tear fluid proteomics multimarkers for diabetic retinopathy screening[J]. BMC Ophthalmol, 2013, 13(1): 40.
    [20] Hirao Y, Saito S, Fujinaka H, et al. Proteome profiling of diabetic mellitus patient urine for discovery of biomarkers by comprehensive MS-based proteomics[J]. Proteomes, 2018, 6(1): E9.
    [21] Campion CG, Sanchez-Ferras O, Batchu SN. Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy[J]. Can J Kidney Health Dis, 2017, 4: 2054358117705371.
    [22] Yoon JJ, Park JH, Kim HJ, et al. Dianthus superbus improves glomerular fibrosis and renal dysfunction in diabetic nephropathy model[J]. Nutrients, 2019, 11(3): E553.
    [23] Thippakorn C, Schaduangrat N, Nantasenamat C. Proteomic and bioinformatic discovery of biomarkers for diabetic nephropathy[J]. EXCLI J, 2018, 17: 312-330.
    [24] de Boer IH, Rue TC, Cleary PA, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort[J]. Arch Intern Med, 2011, 171(5): 412-420.
    [25] Son MK, Yoo HY, Kwak BO, et al. Regression and progression of microalbuminuria in adolescents with childhood onset diabetes mellitus[J]. Ann Pediatr Endocrinol Metab, 2015, 20(1): 13-20.
    [26] van JA, Scholey JW, Konvalinka A. Insights into diabetic kidney disease using urinary proteomics and bioinformatics[J]. J Am Soc Nephrol, 2017, 28(4): 1050-1061.
    [27] Moresco RN, de Carvalho JAM. Applying proteomics to diagnosis of diabetic kidney disease[J]. Expert Rev Proteomics, 2017, 14(10): 841-843.
    [28] Harpole M, Davis J, Espina V. Current state of the art for enhancing urine biomarker discovery[J]. Expert Rev Proteomics, 2016, 13(6): 609-626.
    [29] Papale M, di Paolo S, Vocino G, et al. Proteomics and diabetic nephropathy: what have we learned from a decade of clinical proteomics studies[J]? J Nephrol, 2014, 27(3): 221-228.
    [30] Wende AR. Post-translational modifications of the cardiac proteome in diabetes and heart failure[J]. Proteomics Clin Appl, 2016, 10(1): 25-38.
    [31] Dewey S, Sohal M, Gomes AV. Proteomic analysis of Akita mice reveals 9 proteins altered during early stages of diabetic cardiomyopathy[J]. Biophys J, 2013, 104(2): 313a-314a.
    [32] Pai YW, Lin CH, Lin SY, et al. Reconfirmation of newly discovered risk factors of diabetic peripheral neuropathy in patients with type 2 diabetes: a case-control study[J]. PLoS One, 2019, 14(7): e0220175.
    [33] Hosseini A, Abdollahi M. Diabetic neuropathy and oxidative stress: therapeutic perspectives[J]. Oxid Med Cell Longev, 2013, 2013: 168039.
    [34] Zhang TJ, Gao YB, Gong YB, et al. Tang-Luo-ning improves mitochondrial antioxidase activity in dorsal root Ganglia of diabetic rats: a proteomics study[J]. Biomed Res Int, 2017, 2017: 8176089.
    [35] Singh A, Subramani E, Datta Ray C, et al. Proteomic-driven biomarker discovery in gestational diabetes mellitus: a review[J]. J Proteomics, 2015, 127(Pt A): 44-49.
    [36] Kim SM, Park JS, Norwitz ER, et al. Identification of proteomic biomarkers in maternal plasma in the early second trimester that predict the subsequent development of gestational diabetes[J]. Reprod Sci, 2012, 19(2): 202-209.
    [37] Seyhan AA, Carini C. Are innovation and new technologies in precision medicine paving a new era in patients centric care [J]?J Transl Med, 2019, 17(1): 114.
    [38] Vitzthum F, Behrens F, Anderson NL, et al. Proteomics: from basic research to diagnostic application. A review of requirements & needs[J]. J Proteome Res, 2005, 4(4): 1086-1097.
    [39] Colhoun HM, Marcovecchio ML. Biomarkers of diabetic kidney disease[J]. Diabetologia, 2018, 61(5): 996-1011.
计量
  • 文章访问数: 
  • HTML全文浏览量:  0
  • PDF下载量: 
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-10-29
  • 修回日期:  2020-05-10
  • 刊出日期:  2020-06-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭